Logo

Novartis Reports One Year Results of Beovu (brolucizumabin) in P- III MERLIN Study to Treat Wet Age-Related Macular Degeneration

Share this

Novartis Reports One Year Results of Beovu (brolucizumabin) in P- III MERLIN Study to Treat Wet Age-Related Macular Degeneration

Shots:

  • The P- III MERLIN study involves assessing the efficacy & safety of Beovu (6 mg- q4w) vs aflibercept (2 mg- q4w) following the loading phase in patients with wet AMD who have persistent retinal fluid despite anti-VEGF therapy
  • Results: met its 1EPs i.e. non-inferiority in mean change in BCVA from baseline and superiority on 2EPs @ 1 yrs. Beovu (6mg- q4w) was associated with higher rates of IOI (9.3% vs 4.5%) which includes RV (0.8% vs 0.0%) & RO (2.0% vs 0.0%)- overall rate of vision (4.8% vs 1.7%)
  • Novartis has decided on early termination of the RAPTOR & RAVEN studies- which assessed the efficacy & safety of Beovu in RVO- and included 6 initial monthly injections

  Ref: Novartis | Image: Novartis

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions